Covered recipient · General Payments record
DAVID ECHEVERRI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$2,833.85
- Reported across 171 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $568.69 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $140.25 | 10 |
| PFIZER INC. | $132.15 | 8 |
| Novo Nordisk AS | $81.52 | 5 |
| Lilly USA, LLC | $51.06 | 3 |
| Exact Sciences Corporation | $31.68 | 2 |
| GlaxoSmithKline, LLC. | $30.24 | 2 |
| Theratechnologies Inc. | $26.97 | 1 |
| DEXCOM, INC. | $23.30 | 1 |
| Phathom Pharmaceuticals, Inc. | $19.55 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.68 | 1 |
| Acerta Pharma LLC | $14.29 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $7.82 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674909 | CMS |
| ABBVIE INC. | $29.84 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674911 | CMS |
| ABBVIE INC. | $2.27 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674913 | CMS |
| ABBVIE INC. | $5.91 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674915 | CMS |
| ABBVIE INC. | $15.50 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674917 | CMS |
| ABBVIE INC. | $6.28 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674919 | CMS |
| ABBVIE INC. | $22.56 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674921 | CMS |
| ABBVIE INC. | $18.16 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674923 | CMS |
| ABBVIE INC. | $15.31 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674925 | CMS |
| ABBVIE INC. | $16.60 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103674927 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.29 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110510246 | CMS |
| Dexcom, Inc. | $23.30 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153294861 | CMS |
| Exact Sciences Corporation | $16.15 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125821341 | CMS |
| Exact Sciences Corporation | $15.53 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125821343 | CMS |
| GlaxoSmithKline, LLC. | $13.85 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116386416 | CMS |
| GlaxoSmithKline, LLC. | $16.39 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116230365 | CMS |
| Lilly USA, LLC | $18.78 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136118919 | CMS |
| Lilly USA, LLC | $17.83 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136118921 | CMS |
| Lilly USA, LLC | $14.45 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136127217 | CMS |
| Novo Nordisk Inc | $16.35 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108579768 | CMS |
| Novo Nordisk Inc | $17.30 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108580765 | CMS |
| Novo Nordisk Inc | $17.30 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108579922 | CMS |
| Novo Nordisk Inc | $15.80 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108580321 | CMS |
| Novo Nordisk Inc | $14.77 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108582907 | CMS |
| PFIZER INC. | $17.23 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132041249 | CMS |
| PFIZER INC. | $19.64 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132041371 | CMS |
| PFIZER INC. | $17.25 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132048798 | CMS |
| PFIZER INC. | $19.99 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132047006 | CMS |
| PFIZER INC. | $8.77 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130920304 | CMS |
| PFIZER INC. | $18.85 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132056466 | CMS |
| PFIZER INC. | $14.66 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132111081 | CMS |
| PFIZER INC. | $15.76 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131017957 | CMS |
| Phathom Pharmaceuticals, Inc. | $19.55 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151057765 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.68 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137537168 | CMS |
| Theratechnologies Inc. | $26.97 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092903766 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.